These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15770467)

  • 21. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
    Gallwitz B
    Vasc Health Risk Manag; 2007; 3(2):203-10. PubMed ID: 17580730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide: the time is near.
    Huang A; Raskin P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):249-51. PubMed ID: 15569268
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulation and degradation of GIP and GLP-1.
    Deacon CF
    Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
    Alsalim W; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Jul; 20(7):1652-1658. PubMed ID: 29498469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
    Drucker DJ
    Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
    [No Abstract]   [Full Text] [Related]  

  • 32. Gastro-intestinal hormones GIP and GLP-1.
    Kieffer TJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):13-21. PubMed ID: 15122087
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).
    Zhu L; Tamvakopoulos C; Xie D; Dragovic J; Shen X; Fenyk-Melody JE; Schmidt K; Bagchi A; Griffin PR; Thornberry NA; Sinha Roy R
    J Biol Chem; 2003 Jun; 278(25):22418-23. PubMed ID: 12690116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatments for diabetes.
    Bloomgarden ZT; Inzucchi SE
    N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
    [No Abstract]   [Full Text] [Related]  

  • 35. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
    Holst JJ; Deacon CF
    Curr Opin Pharmacol; 2004 Dec; 4(6):589-96. PubMed ID: 15525549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
    Hinke SA; McIntosh CH; Hoffmann T; Kühn-Wache K; Wagner L; Bär J; Manhart S; Wermann M; Pederson RA; Demuth HU
    Diabetes Care; 2002 Aug; 25(8):1490-1; author reply 1491-2. PubMed ID: 12145269
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Adv Exp Med Biol; 2003; 524():303-12. PubMed ID: 12675252
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.